Clinical Trials Logo

Clinical Trial Summary

Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue in patients after lung transplant. This study is a registry-forming study with concurrent tissue banking from surveillance bronchoscopy in addition to extra tissue sampling of blood and urine. Patients will be characterized by usual clinical phenotyping and the latest imaging methods so that diseased condition underlying CLAD can be better understood.


Clinical Trial Description

Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue that lead to almost 50% mortality within 5 years from the time of lung transplant. In the past CLAD was exclusively occurring in small airways causing a condition called "Bronchiolitis Obliteran Syndrome" (BOS). However, recently many have observed restrictive changes in lung physiology with or without parenchymal abnormalities. This new CLAD is called RAS or RCLAD. What is also concerning is that RAS is thought to be associated with disproportionally high morbidity and mortality. This clinical trial intends to create a registry of patients who completed lung transplant and who are undergoing routine surveillance bronchoscopy. A subgroup of patients will be characterized by hyper polarized gas magnetic resonance image to enhance detection of CLAD, and to be correlated between the MRI imaging results and clinical/biochemical results. This study is anticipated to advance our understanding of CLAD which is currently inevitably fatal outcome among patients after lung transplant. ;


Study Design


Related Conditions & MeSH terms

  • Chronic Rejection of Lung Transplant

NCT number NCT03697395
Study type Interventional
Source University of Virginia
Contact Roselove Asare
Phone 434-243-6074
Email RNN3B@VIRGINIA.EDU
Status Recruiting
Phase Phase 2
Start date April 1, 2019
Completion date December 31, 2038

See also
  Status Clinical Trial Phase
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Recruiting NCT05586906 - Noninvasive Early Detection of Lung Allograft Dysfunction After Lung Transplantation With Multiple Breath Washout Test N/A
Withdrawn NCT04415476 - Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) Phase 2
Completed NCT01650545 - Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Phase 1/Phase 2
Active, not recruiting NCT03657342 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Phase 3